COMBINED TREATMENT OF PLAQUE PSORIASIS WITH JANUS KINASE INHIBITORS: EVALUATION OF EFFICACY AND SAFETY IN PATIENTS WITH MODERATE TO SEVERE DISEASE

Abstract

Plaque psoriasis is a chronic inflammatory disease that affects millions of people worldwide, significantly impacting patients' quality of life. Recent therapeutic advances highlight Janus Kinase (JAK) inhibitors as a promising option for the treatment of moderate to severe forms of the disease. This study aimed to conduct an integrative review to evaluate the efficacy and safety of combined treatment using JAK inhibitors in patients with plaque psoriasis. Clinical trials, systematic reviews, and observational studies published between 2015 and 2024 in databases such as PubMed, Embase, and the Cochrane Library were analyzed. The results demonstrated that JAK inhibitors, in combination with traditional topical or systemic agents, provide significant clinical improvement compared to monotherapies, especially in reducing the Psoriasis Area and Severity Index (PASI). However, the safety profile requires careful monitoring due to the possibility of adverse effects, such as infections and hematologic changes. It is concluded that, despite the promising benefits, the combined use of JAK inhibitors should be individualized, considering the risks and the patient's therapeutic response.